This form of SLE was previously thought to be the main form [167], but the failures in phase 2 clinical trials of multiple TLR7/9 antagonists and antibodies like rontalizumab and sifalimumab that effectively neutralize IFNα, indicate that only 10% or less of SLE patients have SLE2. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.